nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Cisplatin—lung cancer	0.397	0.599	CbGbCtD
Deferoxamine—XDH—Doxorubicin—lung cancer	0.266	0.401	CbGbCtD
Deferoxamine—XDH—Purine catabolism—CAT—lung cancer	0.00238	0.107	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—VIMP—lung cancer	0.00193	0.0861	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—NFE2L2—lung cancer	0.00169	0.0754	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—GCLC—lung cancer	0.00145	0.0648	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—PRDX1—lung cancer	0.00124	0.0555	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—NQO1—lung cancer	0.00122	0.0545	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—JUNB—lung cancer	0.00121	0.0541	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—RRM1—lung cancer	0.00104	0.0463	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—CAT—lung cancer	0.000989	0.0442	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—SOD2—lung cancer	0.000938	0.0419	CbGpPWpGaD
Deferoxamine—XDH—Purine metabolism—CAT—lung cancer	0.000917	0.041	CbGpPWpGaD
Deferoxamine—XDH—Oxidative Stress—CYP1A1—lung cancer	0.000886	0.0396	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—CAT—lung cancer	0.000461	0.0206	CbGpPWpGaD
Deferoxamine—XDH—Nucleotide metabolism—TYMS—lung cancer	0.00044	0.0197	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—CAT—lung cancer	0.000418	0.0187	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—SOD2—lung cancer	0.000397	0.0177	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—APOA1—lung cancer	0.000321	0.0144	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—ALB—lung cancer	0.000255	0.0114	CbGpPWpGaD
Deferoxamine—Hypotension—Irinotecan—lung cancer	0.000251	0.000798	CcSEcCtD
Deferoxamine—Vomiting—Vinblastine—lung cancer	0.000249	0.000793	CcSEcCtD
Deferoxamine—Dizziness—Erlotinib—lung cancer	0.000249	0.000792	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—lung cancer	0.000247	0.000788	CcSEcCtD
Deferoxamine—Headache—Vinblastine—lung cancer	0.000245	0.000781	CcSEcCtD
Deferoxamine—Angioedema—Paclitaxel—lung cancer	0.000245	0.00078	CcSEcCtD
Deferoxamine—Leukopenia—Etoposide—lung cancer	0.000245	0.00078	CcSEcCtD
Deferoxamine—Hypotension—Gemcitabine—lung cancer	0.000244	0.000778	CcSEcCtD
Deferoxamine—Eye disorder—Docetaxel—lung cancer	0.000244	0.000777	CcSEcCtD
Deferoxamine—Anaphylactic shock—Cisplatin—lung cancer	0.000244	0.000776	CcSEcCtD
Deferoxamine—Oedema—Cisplatin—lung cancer	0.000244	0.000776	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—lung cancer	0.000243	0.000775	CcSEcCtD
Deferoxamine—Infection—Cisplatin—lung cancer	0.000242	0.000771	CcSEcCtD
Deferoxamine—Vomiting—Topotecan—lung cancer	0.000242	0.00077	CcSEcCtD
Deferoxamine—Paraesthesia—Irinotecan—lung cancer	0.000241	0.000767	CcSEcCtD
Deferoxamine—Leukopenia—Paclitaxel—lung cancer	0.00024	0.000764	CcSEcCtD
Deferoxamine—Hypersensitivity—Vinorelbine—lung cancer	0.00024	0.000763	CcSEcCtD
Deferoxamine—Vomiting—Erlotinib—lung cancer	0.000239	0.000762	CcSEcCtD
Deferoxamine—Dyspnoea—Irinotecan—lung cancer	0.000239	0.000762	CcSEcCtD
Deferoxamine—Nervous system disorder—Cisplatin—lung cancer	0.000239	0.000761	CcSEcCtD
Deferoxamine—Thrombocytopenia—Cisplatin—lung cancer	0.000238	0.00076	CcSEcCtD
Deferoxamine—Headache—Topotecan—lung cancer	0.000238	0.000759	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000238	0.000758	CcSEcCtD
Deferoxamine—Tachycardia—Cisplatin—lung cancer	0.000238	0.000757	CcSEcCtD
Deferoxamine—Convulsion—Etoposide—lung cancer	0.000237	0.000755	CcSEcCtD
Deferoxamine—Angiopathy—Docetaxel—lung cancer	0.000237	0.000754	CcSEcCtD
Deferoxamine—Skin disorder—Cisplatin—lung cancer	0.000237	0.000754	CcSEcCtD
Deferoxamine—Immune system disorder—Docetaxel—lung cancer	0.000236	0.000751	CcSEcCtD
Deferoxamine—Headache—Erlotinib—lung cancer	0.000236	0.000751	CcSEcCtD
Deferoxamine—Mediastinal disorder—Docetaxel—lung cancer	0.000235	0.000749	CcSEcCtD
Deferoxamine—Asthma—Methotrexate—lung cancer	0.000235	0.000749	CcSEcCtD
Deferoxamine—Paraesthesia—Gemcitabine—lung cancer	0.000235	0.000747	CcSEcCtD
Deferoxamine—Arrhythmia—Docetaxel—lung cancer	0.000233	0.000743	CcSEcCtD
Deferoxamine—Dyspnoea—Gemcitabine—lung cancer	0.000233	0.000742	CcSEcCtD
Deferoxamine—Eosinophilia—Methotrexate—lung cancer	0.000233	0.000741	CcSEcCtD
Deferoxamine—Nausea—Vinblastine—lung cancer	0.000233	0.000741	CcSEcCtD
Deferoxamine—Convulsion—Paclitaxel—lung cancer	0.000232	0.00074	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000232	0.000738	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000231	0.000736	CcSEcCtD
Deferoxamine—Pruritus—Vinorelbine—lung cancer	0.00023	0.000733	CcSEcCtD
Deferoxamine—Pain—Irinotecan—lung cancer	0.000229	0.000731	CcSEcCtD
Deferoxamine—Arthralgia—Paclitaxel—lung cancer	0.000228	0.000727	CcSEcCtD
Deferoxamine—Myalgia—Paclitaxel—lung cancer	0.000228	0.000727	CcSEcCtD
Deferoxamine—Hypotension—Cisplatin—lung cancer	0.000228	0.000725	CcSEcCtD
Deferoxamine—Erythema—Docetaxel—lung cancer	0.000227	0.000724	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000227	0.000722	CcSEcCtD
Deferoxamine—Nausea—Topotecan—lung cancer	0.000226	0.000719	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000226	0.000719	CcSEcCtD
Deferoxamine—Abdominal discomfort—Methotrexate—lung cancer	0.000225	0.000718	CcSEcCtD
Deferoxamine—Pain—Gemcitabine—lung cancer	0.000223	0.000712	CcSEcCtD
Deferoxamine—Nausea—Erlotinib—lung cancer	0.000223	0.000712	CcSEcCtD
Deferoxamine—Anaphylactic shock—Etoposide—lung cancer	0.000223	0.000711	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—PTGS2—lung cancer	0.000223	0.00995	CbGpPWpGaD
Deferoxamine—Diarrhoea—Vinorelbine—lung cancer	0.000223	0.000709	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000222	0.000707	CcSEcCtD
Deferoxamine—Infection—Etoposide—lung cancer	0.000222	0.000706	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—lung cancer	0.000221	0.000703	CcSEcCtD
Deferoxamine—Dysuria—Methotrexate—lung cancer	0.00022	0.0007	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Irinotecan—lung cancer	0.000219	0.000699	CcSEcCtD
Deferoxamine—Anaphylactic shock—Paclitaxel—lung cancer	0.000219	0.000697	CcSEcCtD
Deferoxamine—Oedema—Paclitaxel—lung cancer	0.000219	0.000697	CcSEcCtD
Deferoxamine—Paraesthesia—Cisplatin—lung cancer	0.000219	0.000697	CcSEcCtD
Deferoxamine—Thrombocytopenia—Etoposide—lung cancer	0.000218	0.000696	CcSEcCtD
Deferoxamine—Muscle spasms—Docetaxel—lung cancer	0.000218	0.000696	CcSEcCtD
Deferoxamine—Tachycardia—Etoposide—lung cancer	0.000218	0.000694	CcSEcCtD
Deferoxamine—Infection—Paclitaxel—lung cancer	0.000217	0.000692	CcSEcCtD
Deferoxamine—Dyspnoea—Cisplatin—lung cancer	0.000217	0.000692	CcSEcCtD
Deferoxamine—Skin disorder—Etoposide—lung cancer	0.000217	0.00069	CcSEcCtD
Deferoxamine—Shock—Paclitaxel—lung cancer	0.000215	0.000686	CcSEcCtD
Deferoxamine—Dizziness—Vinorelbine—lung cancer	0.000215	0.000685	CcSEcCtD
Deferoxamine—Nervous system disorder—Paclitaxel—lung cancer	0.000215	0.000683	CcSEcCtD
Deferoxamine—Thrombocytopenia—Paclitaxel—lung cancer	0.000214	0.000682	CcSEcCtD
Deferoxamine—Tachycardia—Paclitaxel—lung cancer	0.000214	0.00068	CcSEcCtD
Deferoxamine—Skin disorder—Paclitaxel—lung cancer	0.000213	0.000677	CcSEcCtD
Deferoxamine—Abdominal pain—Irinotecan—lung cancer	0.000212	0.000675	CcSEcCtD
Deferoxamine—Body temperature increased—Irinotecan—lung cancer	0.000212	0.000675	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Cisplatin—lung cancer	0.00021	0.00067	CcSEcCtD
Deferoxamine—Infestation—Methotrexate—lung cancer	0.00021	0.000668	CcSEcCtD
Deferoxamine—Infestation NOS—Methotrexate—lung cancer	0.00021	0.000668	CcSEcCtD
Deferoxamine—Hypotension—Etoposide—lung cancer	0.000209	0.000664	CcSEcCtD
Deferoxamine—Pain—Cisplatin—lung cancer	0.000208	0.000663	CcSEcCtD
Deferoxamine—Vomiting—Vinorelbine—lung cancer	0.000207	0.000659	CcSEcCtD
Deferoxamine—Body temperature increased—Gemcitabine—lung cancer	0.000207	0.000658	CcSEcCtD
Deferoxamine—Renal failure—Methotrexate—lung cancer	0.000206	0.000656	CcSEcCtD
Deferoxamine—Hypotension—Paclitaxel—lung cancer	0.000204	0.000651	CcSEcCtD
Deferoxamine—Headache—Vinorelbine—lung cancer	0.000204	0.000649	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—lung cancer	0.000204	0.000648	CcSEcCtD
Deferoxamine—Leukopenia—Docetaxel—lung cancer	0.000203	0.000648	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—lung cancer	0.000202	0.000642	CcSEcCtD
Deferoxamine—Paraesthesia—Etoposide—lung cancer	0.0002	0.000638	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000199	0.000635	CcSEcCtD
Deferoxamine—Dyspnoea—Etoposide—lung cancer	0.000199	0.000634	CcSEcCtD
Deferoxamine—Hypersensitivity—Irinotecan—lung cancer	0.000198	0.00063	CcSEcCtD
Deferoxamine—Convulsion—Docetaxel—lung cancer	0.000197	0.000627	CcSEcCtD
Deferoxamine—Paraesthesia—Paclitaxel—lung cancer	0.000196	0.000626	CcSEcCtD
Deferoxamine—Dyspnoea—Paclitaxel—lung cancer	0.000195	0.000621	CcSEcCtD
Deferoxamine—Arthralgia—Docetaxel—lung cancer	0.000193	0.000616	CcSEcCtD
Deferoxamine—Myalgia—Docetaxel—lung cancer	0.000193	0.000616	CcSEcCtD
Deferoxamine—Nausea—Vinorelbine—lung cancer	0.000193	0.000615	CcSEcCtD
Deferoxamine—XDH—Metabolism—COL4A3BP—lung cancer	0.000193	0.00861	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—AZIN2—lung cancer	0.000193	0.00861	CbGpPWpGaD
Deferoxamine—Gastrointestinal disorder—Etoposide—lung cancer	0.000193	0.000614	CcSEcCtD
Deferoxamine—Body temperature increased—Cisplatin—lung cancer	0.000193	0.000613	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000192	0.000612	CcSEcCtD
Deferoxamine—Pain—Etoposide—lung cancer	0.000191	0.000608	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—lung cancer	0.00019	0.000606	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000189	0.000602	CcSEcCtD
Deferoxamine—Pain—Paclitaxel—lung cancer	0.000187	0.000596	CcSEcCtD
Deferoxamine—Urinary tract disorder—Methotrexate—lung cancer	0.000186	0.000592	CcSEcCtD
Deferoxamine—Anaphylactic shock—Docetaxel—lung cancer	0.000185	0.000591	CcSEcCtD
Deferoxamine—Oedema—Docetaxel—lung cancer	0.000185	0.000591	CcSEcCtD
Deferoxamine—Pruritus—Gemcitabine—lung cancer	0.000185	0.000589	CcSEcCtD
Deferoxamine—Urethral disorder—Methotrexate—lung cancer	0.000184	0.000587	CcSEcCtD
Deferoxamine—Infection—Docetaxel—lung cancer	0.000184	0.000587	CcSEcCtD
Deferoxamine—Diarrhoea—Irinotecan—lung cancer	0.000184	0.000585	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Etoposide—lung cancer	0.000182	0.000581	CcSEcCtD
Deferoxamine—Shock—Docetaxel—lung cancer	0.000182	0.000581	CcSEcCtD
Deferoxamine—Nervous system disorder—Docetaxel—lung cancer	0.000182	0.000579	CcSEcCtD
Deferoxamine—Thrombocytopenia—Docetaxel—lung cancer	0.000182	0.000578	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—lung cancer	0.000181	0.000578	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—lung cancer	0.000181	0.000578	CcSEcCtD
Deferoxamine—Visual impairment—Methotrexate—lung cancer	0.000181	0.000577	CcSEcCtD
Deferoxamine—Tachycardia—Docetaxel—lung cancer	0.000181	0.000576	CcSEcCtD
Deferoxamine—Skin disorder—Docetaxel—lung cancer	0.00018	0.000574	CcSEcCtD
Deferoxamine—Hypersensitivity—Cisplatin—lung cancer	0.000179	0.000572	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Paclitaxel—lung cancer	0.000179	0.00057	CcSEcCtD
Deferoxamine—Diarrhoea—Gemcitabine—lung cancer	0.000179	0.00057	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—lung cancer	0.000178	0.000568	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—lung cancer	0.000178	0.000567	CcSEcCtD
Deferoxamine—Dizziness—Irinotecan—lung cancer	0.000177	0.000565	CcSEcCtD
Deferoxamine—Urticaria—Etoposide—lung cancer	0.000177	0.000565	CcSEcCtD
Deferoxamine—Body temperature increased—Etoposide—lung cancer	0.000176	0.000562	CcSEcCtD
Deferoxamine—Abdominal pain—Etoposide—lung cancer	0.000176	0.000562	CcSEcCtD
Deferoxamine—Eye disorder—Methotrexate—lung cancer	0.000176	0.00056	CcSEcCtD
Deferoxamine—Tinnitus—Methotrexate—lung cancer	0.000175	0.000559	CcSEcCtD
Deferoxamine—Urticaria—Paclitaxel—lung cancer	0.000174	0.000554	CcSEcCtD
Deferoxamine—Hypotension—Docetaxel—lung cancer	0.000173	0.000552	CcSEcCtD
Deferoxamine—Abdominal pain—Paclitaxel—lung cancer	0.000173	0.000551	CcSEcCtD
Deferoxamine—Body temperature increased—Paclitaxel—lung cancer	0.000173	0.000551	CcSEcCtD
Deferoxamine—Angiopathy—Methotrexate—lung cancer	0.000171	0.000544	CcSEcCtD
Deferoxamine—Vomiting—Irinotecan—lung cancer	0.000171	0.000543	CcSEcCtD
Deferoxamine—Immune system disorder—Methotrexate—lung cancer	0.00017	0.000541	CcSEcCtD
Deferoxamine—Mediastinal disorder—Methotrexate—lung cancer	0.00017	0.00054	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000169	0.000538	CcSEcCtD
Deferoxamine—Headache—Irinotecan—lung cancer	0.000168	0.000535	CcSEcCtD
Deferoxamine—Diarrhoea—Cisplatin—lung cancer	0.000167	0.000531	CcSEcCtD
Deferoxamine—Paraesthesia—Docetaxel—lung cancer	0.000167	0.00053	CcSEcCtD
Deferoxamine—Vomiting—Gemcitabine—lung cancer	0.000166	0.000529	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—lung cancer	0.000166	0.000528	CcSEcCtD
Deferoxamine—Dyspnoea—Docetaxel—lung cancer	0.000165	0.000527	CcSEcCtD
Deferoxamine—Hypersensitivity—Etoposide—lung cancer	0.000164	0.000524	CcSEcCtD
Deferoxamine—XDH—Metabolism—ATP5H—lung cancer	0.000164	0.00732	CbGpPWpGaD
Deferoxamine—Erythema—Methotrexate—lung cancer	0.000164	0.000522	CcSEcCtD
Deferoxamine—Headache—Gemcitabine—lung cancer	0.000164	0.000521	CcSEcCtD
Deferoxamine—Hypersensitivity—Paclitaxel—lung cancer	0.000161	0.000513	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—lung cancer	0.000161	0.000512	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Docetaxel—lung cancer	0.00016	0.00051	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—lung cancer	0.00016	0.00051	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—lung cancer	0.00016	0.000509	CcSEcCtD
Deferoxamine—Nausea—Irinotecan—lung cancer	0.000159	0.000508	CcSEcCtD
Deferoxamine—Pain—Docetaxel—lung cancer	0.000159	0.000505	CcSEcCtD
Deferoxamine—Pruritus—Etoposide—lung cancer	0.000158	0.000503	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—lung cancer	0.000157	0.0005	CcSEcCtD
Deferoxamine—Nausea—Gemcitabine—lung cancer	0.000155	0.000494	CcSEcCtD
Deferoxamine—Vomiting—Cisplatin—lung cancer	0.000155	0.000493	CcSEcCtD
Deferoxamine—Pruritus—Paclitaxel—lung cancer	0.000155	0.000493	CcSEcCtD
Deferoxamine—Vision blurred—Methotrexate—lung cancer	0.000154	0.000492	CcSEcCtD
Deferoxamine—Diarrhoea—Etoposide—lung cancer	0.000153	0.000486	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—lung cancer	0.000152	0.000485	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—lung cancer	0.000152	0.000484	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Docetaxel—lung cancer	0.000152	0.000483	CcSEcCtD
Deferoxamine—Diarrhoea—Paclitaxel—lung cancer	0.00015	0.000477	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—lung cancer	0.000148	0.000471	CcSEcCtD
Deferoxamine—Dizziness—Etoposide—lung cancer	0.000148	0.00047	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—lung cancer	0.000147	0.000469	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—lung cancer	0.000147	0.000468	CcSEcCtD
Deferoxamine—Abdominal pain—Docetaxel—lung cancer	0.000147	0.000467	CcSEcCtD
Deferoxamine—Body temperature increased—Docetaxel—lung cancer	0.000147	0.000467	CcSEcCtD
Deferoxamine—Leukopenia—Methotrexate—lung cancer	0.000147	0.000467	CcSEcCtD
Deferoxamine—XDH—Metabolism—PLBD1—lung cancer	0.000146	0.00653	CbGpPWpGaD
Deferoxamine—Arrhythmia—Doxorubicin—lung cancer	0.000146	0.000464	CcSEcCtD
Deferoxamine—Dizziness—Paclitaxel—lung cancer	0.000145	0.000461	CcSEcCtD
Deferoxamine—Nausea—Cisplatin—lung cancer	0.000145	0.000461	CcSEcCtD
Deferoxamine—Convulsion—Methotrexate—lung cancer	0.000142	0.000452	CcSEcCtD
Deferoxamine—Vomiting—Etoposide—lung cancer	0.000142	0.000452	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—lung cancer	0.000142	0.000452	CcSEcCtD
Deferoxamine—Headache—Etoposide—lung cancer	0.00014	0.000445	CcSEcCtD
Deferoxamine—Arthralgia—Methotrexate—lung cancer	0.000139	0.000444	CcSEcCtD
Deferoxamine—Myalgia—Methotrexate—lung cancer	0.000139	0.000444	CcSEcCtD
Deferoxamine—Vomiting—Paclitaxel—lung cancer	0.000139	0.000443	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000138	0.000441	CcSEcCtD
Deferoxamine—Headache—Paclitaxel—lung cancer	0.000137	0.000437	CcSEcCtD
Deferoxamine—Hypersensitivity—Docetaxel—lung cancer	0.000137	0.000435	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—lung cancer	0.000136	0.000434	CcSEcCtD
Deferoxamine—Anaphylactic shock—Methotrexate—lung cancer	0.000134	0.000426	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—lung cancer	0.000134	0.000426	CcSEcCtD
Deferoxamine—XDH—Metabolism—HSD17B10—lung cancer	0.000134	0.00597	CbGpPWpGaD
Deferoxamine—Infection—Methotrexate—lung cancer	0.000133	0.000423	CcSEcCtD
Deferoxamine—Nausea—Etoposide—lung cancer	0.000133	0.000422	CcSEcCtD
Deferoxamine—Pruritus—Docetaxel—lung cancer	0.000131	0.000418	CcSEcCtD
Deferoxamine—Nervous system disorder—Methotrexate—lung cancer	0.000131	0.000418	CcSEcCtD
Deferoxamine—Thrombocytopenia—Methotrexate—lung cancer	0.000131	0.000417	CcSEcCtD
Deferoxamine—Nausea—Paclitaxel—lung cancer	0.00013	0.000414	CcSEcCtD
Deferoxamine—Skin disorder—Methotrexate—lung cancer	0.00013	0.000414	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—lung cancer	0.000127	0.000404	CcSEcCtD
Deferoxamine—Diarrhoea—Docetaxel—lung cancer	0.000127	0.000404	CcSEcCtD
Deferoxamine—Hypotension—Methotrexate—lung cancer	0.000125	0.000398	CcSEcCtD
Deferoxamine—XDH—Metabolism—CKB—lung cancer	0.000124	0.00555	CbGpPWpGaD
Deferoxamine—Convulsion—Doxorubicin—lung cancer	0.000123	0.000391	CcSEcCtD
Deferoxamine—Dizziness—Docetaxel—lung cancer	0.000123	0.000391	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000122	0.000388	CcSEcCtD
Deferoxamine—XDH—Selenium Micronutrient Network—IL6—lung cancer	0.000121	0.00542	CbGpPWpGaD
Deferoxamine—Myalgia—Doxorubicin—lung cancer	0.000121	0.000385	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—lung cancer	0.000121	0.000385	CcSEcCtD
Deferoxamine—Paraesthesia—Methotrexate—lung cancer	0.00012	0.000382	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.00012	0.000382	CcSEcCtD
Deferoxamine—Dyspnoea—Methotrexate—lung cancer	0.000119	0.00038	CcSEcCtD
Deferoxamine—Vomiting—Docetaxel—lung cancer	0.000118	0.000376	CcSEcCtD
Deferoxamine—XDH—Metabolism—CNDP2—lung cancer	0.000117	0.00522	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTM2—lung cancer	0.000117	0.00522	CbGpPWpGaD
Deferoxamine—Headache—Docetaxel—lung cancer	0.000116	0.00037	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—lung cancer	0.000116	0.000369	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—lung cancer	0.000116	0.000369	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000115	0.000368	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—lung cancer	0.000115	0.000366	CcSEcCtD
Deferoxamine—Pain—Methotrexate—lung cancer	0.000114	0.000364	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—lung cancer	0.000114	0.000363	CcSEcCtD
Deferoxamine—XDH—Metabolism—MTMR3—lung cancer	0.000114	0.00508	CbGpPWpGaD
Deferoxamine—Nervous system disorder—Doxorubicin—lung cancer	0.000114	0.000362	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—lung cancer	0.000113	0.000361	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—lung cancer	0.000113	0.00036	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—lung cancer	0.000112	0.000358	CcSEcCtD
Deferoxamine—XDH—Metabolism—PGAM1—lung cancer	0.000111	0.00495	CbGpPWpGaD
Deferoxamine—Nausea—Docetaxel—lung cancer	0.00011	0.000351	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Methotrexate—lung cancer	0.000109	0.000348	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—lung cancer	0.000108	0.000344	CcSEcCtD
Deferoxamine—Urticaria—Methotrexate—lung cancer	0.000106	0.000338	CcSEcCtD
Deferoxamine—Abdominal pain—Methotrexate—lung cancer	0.000106	0.000337	CcSEcCtD
Deferoxamine—Body temperature increased—Methotrexate—lung cancer	0.000106	0.000337	CcSEcCtD
Deferoxamine—XDH—Metabolism—CYP2A7—lung cancer	0.000106	0.00472	CbGpPWpGaD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000105	0.000336	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—lung cancer	0.000104	0.000331	CcSEcCtD
Deferoxamine—XDH—Metabolism—SDC4—lung cancer	0.000103	0.00462	CbGpPWpGaD
Deferoxamine—Dyspnoea—Doxorubicin—lung cancer	0.000103	0.000329	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—lung cancer	9.99e-05	0.000318	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—lung cancer	9.9e-05	0.000315	CcSEcCtD
Deferoxamine—Hypersensitivity—Methotrexate—lung cancer	9.85e-05	0.000314	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—lung cancer	9.46e-05	0.000301	CcSEcCtD
Deferoxamine—Pruritus—Methotrexate—lung cancer	9.46e-05	0.000301	CcSEcCtD
Deferoxamine—XDH—Metabolism—RRM1—lung cancer	9.41e-05	0.00421	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTA3—lung cancer	9.41e-05	0.00421	CbGpPWpGaD
Deferoxamine—Urticaria—Doxorubicin—lung cancer	9.19e-05	0.000293	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—lung cancer	9.15e-05	0.000291	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—lung cancer	9.15e-05	0.000291	CcSEcCtD
Deferoxamine—Diarrhoea—Methotrexate—lung cancer	9.15e-05	0.000291	CcSEcCtD
Deferoxamine—XDH—Metabolism—B4GALT5—lung cancer	8.85e-05	0.00395	CbGpPWpGaD
Deferoxamine—Dizziness—Methotrexate—lung cancer	8.84e-05	0.000282	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTA4—lung cancer	8.61e-05	0.00385	CbGpPWpGaD
Deferoxamine—Hypersensitivity—Doxorubicin—lung cancer	8.53e-05	0.000272	CcSEcCtD
Deferoxamine—Vomiting—Methotrexate—lung cancer	8.5e-05	0.000271	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTA2—lung cancer	8.39e-05	0.00375	CbGpPWpGaD
Deferoxamine—Headache—Methotrexate—lung cancer	8.37e-05	0.000267	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—lung cancer	8.19e-05	0.000261	CcSEcCtD
Deferoxamine—XDH—Metabolism—GSTA1—lung cancer	8.09e-05	0.00362	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ABCC3—lung cancer	8e-05	0.00358	CbGpPWpGaD
Deferoxamine—Nausea—Methotrexate—lung cancer	7.94e-05	0.000253	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—lung cancer	7.92e-05	0.000252	CcSEcCtD
Deferoxamine—XDH—Metabolism—AKR1C1—lung cancer	7.75e-05	0.00346	CbGpPWpGaD
Deferoxamine—Dizziness—Doxorubicin—lung cancer	7.65e-05	0.000244	CcSEcCtD
Deferoxamine—XDH—Metabolism—UGT1A1—lung cancer	7.52e-05	0.00336	CbGpPWpGaD
Deferoxamine—Vomiting—Doxorubicin—lung cancer	7.36e-05	0.000234	CcSEcCtD
Deferoxamine—XDH—Metabolism—GNG11—lung cancer	7.25e-05	0.00324	CbGpPWpGaD
Deferoxamine—Headache—Doxorubicin—lung cancer	7.25e-05	0.000231	CcSEcCtD
Deferoxamine—XDH—Metabolism—ALDOA—lung cancer	6.91e-05	0.00309	CbGpPWpGaD
Deferoxamine—Nausea—Doxorubicin—lung cancer	6.87e-05	0.000219	CcSEcCtD
Deferoxamine—XDH—Metabolism—NCOA3—lung cancer	6.71e-05	0.003	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ADCY1—lung cancer	6.52e-05	0.00292	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ABCG2—lung cancer	6.52e-05	0.00292	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ENO2—lung cancer	6.4e-05	0.00286	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HPGDS—lung cancer	6.4e-05	0.00286	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PPP2R1B—lung cancer	6.36e-05	0.00284	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTT1—lung cancer	6.2e-05	0.00277	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GCLC—lung cancer	6.13e-05	0.00274	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP2A6—lung cancer	6.13e-05	0.00274	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ENO1—lung cancer	5.81e-05	0.0026	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP2E1—lung cancer	5.21e-05	0.00233	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—NQO1—lung cancer	5.16e-05	0.0023	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—STK11—lung cancer	4.65e-05	0.00208	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTP1—lung cancer	4.3e-05	0.00192	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CAT—lung cancer	4.19e-05	0.00187	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ABCB1—lung cancer	4.07e-05	0.00182	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—TYMS—lung cancer	4e-05	0.00179	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—GSTM1—lung cancer	3.95e-05	0.00177	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CYP1A1—lung cancer	3.75e-05	0.00167	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ERCC2—lung cancer	3.72e-05	0.00166	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—APOA1—lung cancer	3.21e-05	0.00144	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CG—lung cancer	2.93e-05	0.00131	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—POMC—lung cancer	2.79e-05	0.00125	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—CREBBP—lung cancer	2.72e-05	0.00122	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CD—lung cancer	2.58e-05	0.00115	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—ALB—lung cancer	2.55e-05	0.00114	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CB—lung cancer	2.25e-05	0.00101	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PTGS2—lung cancer	2.23e-05	0.000996	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PTEN—lung cancer	1.94e-05	0.000868	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—EP300—lung cancer	1.85e-05	0.000828	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—PIK3CA—lung cancer	1.37e-05	0.000613	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—AKT1—lung cancer	1.12e-05	0.000501	CbGpPWpGaD
